Guy Furness
Publisher & Proprietor

Is this your profile?

About

Guy Furness is an independent publisher specialising in the global drug delivery industry.

Prior to launching ONdrugDelivery in 2004, he worked as a freelance drug delivery journalist and, before that, he set-up and was Editor of a global drug delivery industry sister newsletter to Scrip World Pharmaceutical News (now Informa Pharma Intelligence).

Mr Furness has written for leading industry magazines and journals, business reports and national newspapers, including The Times newspaper (UK). He has also occasionally written on behalf of industry, including for leading US and European drug delivery and related companies.

It was during his time as a freelance drug delivery writer that Mr Furness recognised the pressing need (at that time unmet) for a niche industry information and intelligence provider able to concentrate not merely on the drug delivery industry as a whole, but to focus right down into specific topics within the field of drug delivery. This is why ONdrugDelivery Magazine was created.

Mr Furness advises several event organisers on pertinent programme content and has himself spoken on drug delivery at international pharmaceutical conferences. He began his career as a member of the editorial team of the pharmaceutical R&D products database, Pharmaprojects (owned by Informa PLC). He graduated from the University of Bath (UK) in 1998 with a BSc (Hons) in Natural Sciences.

Contributions

A GAME CHANGER FOR HIGH-RISK MEDICATIONS VIA AN INTRANASAL DELIVERY PLATFORM

Marcel Botha, Andreas Bilstein, Houssam Elghobary and Rouven Kraus discuss the benefits of the Validose digital health platform for the safe delivery of high-value and/or high-risk products.

More contributions

HOW DIGITAL THERAPEUTICS ADD VALUE TO TREATMENTS FOR COMPLEX CONDITIONS

Romain Marmot discusses how external partners with a track record of developing digital therapeutics for numerous chronic conditions and therapies can help life science organisations implement digital solutions across their pipeline, adding value to each therapy while improving medication adherence and clinical outcomes.

HOW DIGITAL UX IN CLINICAL TRIALS CAN IMPROVE MEASURES

Ben Cox discusses the key challenges, principles and advantages of following a user-experience approach to digital health technologies in clinical trials.

#133_2022_May_Injectables_Haselmeier_Featured1

EXCELLENCE THROUGH SIMPLICITY: PICCOJECT™ AUTOINJECTOR PLATFORM

Fred Metzmann and Chris Muenzer discuss the simplicity of the PiccoJect™ autoinjector platform and the company's commitment to sustainability.

#133_2022_May_Xeris_Xeriject_Featured1

XERIJECT™: NON-AQUEOUS FORMULATIONS FOR SC INJECTION OF ULTRA-HIGH-CONCENTRATION BIOLOGICS

Steven Prestrelski introduces the XeriJect non-aqueous formulation technology that creates formulations with visco-elastic properties, opening the door to subcutaneous injection of difficult-to-formulate biologics, such as monoclonal antibodies, at very high concentrations.

SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: THE ROUTE TO FURTHER IMPROVEMENTS

Emil Fraenkel and Bjarne Sørensen investigate the route to further sustainability improvements for the Aria autoinjector. This article is a sequel to a benchmark study on the environmental impact of Aria presented by Phillips-Medisize in ONdrugDelivery Issue 126 (Oct/Nov 2021).

CONFERENCE SHOWCASE

Conference Showcase: Pharmapack Europe 2022 – Education, Innovation, Networking

Pharmapack 2022 takes place in-person at Paris Expo on May 18–19, 2022. The two day in-person event will host more than 50 sessions (online and in-person), networking with 300+ exhibitors covering the pharma packaging and drug delivery industry,and live conference sessions covering three tracks. As a smart event, digital on-demand sessions and other resources are available for a week before and after the physical show.

INTERVIEW: JON LENN & JON VOLMER, MEDPHARM

Jon Lenn and Jon Volmer talked with Guy Furness about the importance of nasal modelling, focusing on MedPharm’s own nasal cavity modelling technology, MedCast, its unique characteristics and benefits and the value it brings to the company’s offering for nasally delivered products.

TRIALS WITHOUT TRIBULATIONS: A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED AND HYBRID CLINICAL TRIALS

Rebecca Beck and Hervé Monchoix discuss how stakeholder needs are driving the development of a new, connected injection device from BD, to support decentralised and hybrid clinical trials.

SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: A LIFECYCLE ASSESSMENT

Emil Fraenkel and Bjarne Sørensen consider the sustainability of re-usable and disposable autoinjectors, its implications in adding connectivity to drug delivery devices and how it has been an important consideration for Phillips-Medisize in the development of the Aria re-usable autoinjector.

INTERVIEW WITH MATHIAS ROMACKER, EX-PFIZER, INJECTION DEVICES STRATEGY CONSULTANT

In this exclusive interview, Mathias Romacker discusses a broad range of topics, from his professional expertise and history seeing the parenteral sector evolve first-hand, to his personal experience as a Crohn’s disease patient making use of the very devices he’s seen grow and develop.

HERE TODAY AND DEFINITELY NOT GONE TOMORROW: WHY SIMPLICITY AND EASE OF USE ARE THE KEY FOR A NEW GENERATION OF REUSABLE INJECTORS

Kate Hudson-Farmer discusses how a new electronic reusable autoinjector – the Aria Smart Autoinjector from Phillips-Medisize – has been designed and user-tested to challenge the preconceived ease-of-use notions about electronic autoinjectors, in addition to addressing how macro trends and personal consumer subtleties could become increasingly important in creating a competitive position as devices seek to improve patient engagement.

PRODUCT SHOWCASE: Evonik’s newly launched EUDRACAP™ functional, ready-to-fill capsules

Evonik introduces EUDRACAP™, its newly launched platform of functional ready-to-fill HPMC capsules, which helps optimise release profile, protects sensitive active ingredients, and speeds time to market.

INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY

Benjamin Dietiker, Weidmann Medical Technology, talks with ONdrugDelivery about how the company has successfully implemented a growth strategy by focusing on key areas, plans for expansion, the effect of covid-19 on the business, and how the company differentiates itself from larger competitors by focusing on quality and service.

CONSIDERATIONS FOR DEVICE SELECTION IN PARENTERAL APPLICATIONS

Mark Tunkel looks at the challenges involved in the selection of drug devices for combination products and the optimisation of the development process.

MG2 AUTOMATION SOLUTIONS FOR INHALATION: R&D, TECHNOLOGICAL PARTNERSHIPS & SUCCESSFUL CASE HISTORIES

Italian automation solutions provider MG2 describes its offering in the inhalation space, including unique benefits of collaboration and two example partnerships.

AEROGEN JOINS FORCES WITH 15 COMPANIES FOR COVID-19 INHALED THERAPIES

Aerogen has revealed details of a broad collaborative effort with more than 15 pharmaceutical companies for the development of covid-19 vaccines and treatments, including one with Synairgen for Solo/Ultra nebuliser-delivered SNG001 (inhaled interferon-beta-1a).

OPTIMA COVID-19 VACCINE FILLING SYSTEM DELIVERED TO CATALENT IN THE US

Optima has delivered a second vial filling system to Catalent's biologics facility in Bloomington, IN, US, to be used initially for the filling of a vaccine candidate to fight covid-19 (SARS-CoV-2).

INTERVIEW WITH AARON MANN, CHIEF EXECUTIVE OFFICER, KINDEVA

In this exclusive interview with ONdrugDelivery, Aaron Mann discusses how Kindeva is positioned to move forward as a major CDMO specialising in inhalation and transdermal dosage forms, having been formed from 3M’s drug delivery in May 2020. We also cover the impact of Covid-19, environmental sustainability, and current challenges faced by the pharmaceutical industry.

VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH

Vaxess Technologies is to receive US BARDA funding to demonstrate the feasibility of its MIMIX microneedle patch technology for a COVID-19 vaccine, with the aim of designing and developing a “combination seasonal protection patch”, incorporating COVID-19 + seasonal influenza protection.

INTERVIEW WITH MARIA FLYNN, ADARE PHARMACEUTICALS

Adare Pharma's Maria Flynn talks with ONdrugDelivery about trends in the oral drug development and delivery space, completing the Orbis Biosciences acquisition during a global pandemic, and how the excellent technology portfolio and strategic fit between Orbis and Adare form part of the combined organisation’s unique story.

Chalmers University Pilot Project Developing Nasal spray to deliver vaccine against COVID-19

A unique concept for a nasal spray mRNA vaccine against covid-19 is being investigated in a new pilot project. The Swedish group is exploring design principles for nasal immunisation, developing a biomimetic nanoparticle provided with both immune enhancers and a targeting protein.

INTERVIEW WITH STEVEN KAUFMAN, STEVANATO & URI BARUCH, CDP

Steven Kaufman and Uri Baruch discuss the recently announced collaboration between their two companies to accelerate the development of a new variable-dose, cartridge-based pen injector platform for diabetes.

WHICH IS THE BETTER TOXICITY TESTING STRATEGY FOR COMBINATION DEVICES?

Mark Turner explores the issue of toxicity testing for combination devices and asks which is the better testing strategy – ISO 10993 or extractables and leachables?

Prev
1
2

Top